Positive results in the ChronSeal®-study

Positive results in the ChronSeal®-study

As was made public earlier the multi-center study conducted in Sweden
and Norway on ChronSeal® for the treatment of chronic leg wounds is now
completed. In the study two dose concentrations were compared with
placebo. Precise results of the study may not be disclosed to the public
yet in consideration of ongoing licensing discussions with a potential
license-candidate, who has the contractual privilege to the study
results. However, we can report that a positive effect on the healing of
the wounds was obtained in those patients receiving active drug. No drug
related serious adverse events were reported.  Studies are now being
planned for finding the optimal dose and treatment duration for
obtaining the best treatment results.
 
 
“We are very pleased with the positive outcome of the ChronSeal® study.
Of course we are sorry that we cannot disclose the precise results just
yet, however, it is more important for ChronTech that the discussions
with our potential partner continues smoothly” says Anders Vahlne, CEO
of ChronTech Pharma.
 
 
 
For more information, please contact:
Anders Vahlne, CEO and Head of Research, ChronTech Pharma AB
Tel: +46 8 5858 1313, mobile phone: +46 709 28 05 28,
E-mail: anders.vahlne@ki.se (anders.vahlne@ki.se)
 
 
 
About ChronTech
ChronTech develops the therapeutic DNA vaccines ChronVac-C® and
ChronVac-B drugs against chronic hepatitis C virus and hepatitis B virus
infections, i.e. chronic infections with jaundice causing viruses which
can lead to liver cirrhosis and liver cancer. ChronTech has also
developed and further develops a patent pending new type of injection
needle for a more effective uptake of DNA vaccines. ChronTech also have
part ownership in the wound healing therapy ChronSeal®, and in the new
platform technology RAS®. The ChronTech share is admitted to trade on
First North. Remium AB is Certified Adviser for ChronTech. For more
information, please visit: www.chrontech.se (http://www.chrontech.se/)
 
In the event of any discrepancy between the Swedish and English versions
of this press release, the Swedish version will take precedence.